Related references
Note: Only part of the references are listed.Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association
Chia-Chin Wu et al.
Nature Communications (2022)
Standardization of PD-L1 immunohistochemistry
Sandra Martinez-Morilla et al.
MODERN PATHOLOGY (2022)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
Soomin Ahn et al.
MODERN PATHOLOGY (2021)
Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study
Ilya Tsimafeyeu et al.
SCIENTIFIC REPORTS (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen
Amanda Vannitamby et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Jeffrey M. Conroy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry
David Jonathan Duncan et al.
PLOS ONE (2019)
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens
Amanda Vannitamby et al.
LUNG CANCER (2019)
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma
Swati Gupta et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
Wen-jun Xiao et al.
FRONTIERS IN ONCOLOGY (2019)
PD-L1 assessment in urothelial carcinoma: a practical approach
Markus Eckstein et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
MET is overexpressed in microsatellite instability-high gastric carcinoma
Jongmin Sim et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer
You Jeong Heo et al.
PRECISION AND FUTURE MEDICINE (2019)
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression
Maria Tretiakova et al.
MODERN PATHOLOGY (2018)
The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?
Keith M. Kerr
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Gene Expression Detection Assay for Cancer Clinical Use
Shavira Narrandes et al.
JOURNAL OF CANCER (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer
Reinhard Buttner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity
Charny Park et al.
ONCOIMMUNOLOGY (2017)
Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer
Ramona Erber et al.
ANTICANCER RESEARCH (2017)
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Straightforward and sensitive RT-qPCR based gene expression analysis of FFPE samples
Fjoralba Zeka et al.
SCIENTIFIC REPORTS (2016)
PD-L1 Testing in Cancer Challenges in Companion Diagnostic Development
Aaron R. Hansen et al.
JAMA ONCOLOGY (2016)
PD-L1 Expression as a Predictive Biomarker Is Absence of Proof the Same as Proof of Absence?
Feriyl Bhaijee et al.
JAMA ONCOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq
Ping Li et al.
BMC GENOMICS (2014)
Targeted RNA-Sequencing with Competitive Multiplex-PCR Amplicon Libraries
Thomas M. Blomquist et al.
PLOS ONE (2013)
Real-time PCR in clinical practice: a powerful tool for evaluating Leishmania chagasi loads in naturally infected dogs
R. N. da Silva et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2010)
RNA expression analysis of formalin-fixed paraffin-embedded tumors
Shannon K. Penland et al.
LABORATORY INVESTIGATION (2007)
Share Paper
